Summit Therapeutics Share Discussion Threads

[poseidon2] 19/10/2016 16:25

Warren Buffett considering a massive stake?

[football] 19/10/2016 16:00

What's the code for 3 shares traded seeing we've had the 2 and 1 trades

[someuwin] 19/10/2016 13:36

It's waking up now.

[waterloo01] 19/10/2016 13:02

Don't see any change in adr nor AIM holdings.

[patviera] 19/10/2016 12:59

Just been dealing in adr

[chrisatrdg] 19/10/2016 12:59

The shareholder numbers are those per 2015 RNS - 27th March 2015 I also note I have not received an e-mail but it could be that the RNS has the wrong numbers.

Edit: Just checked it is just a technicality as to current % but there has been no increase in shares.

[waterloo01] 19/10/2016 12:53

clarkey26, It's not a change in ownership as same number of shares held. Positive is they haven't unloaded any and are clearly in for the big DMD prize.

[chrisatrdg] 19/10/2016 12:52

Lansdowne Partners,as I understand it,have always supported DMD development always showing faith and clearly believe that Summits DMD drugs are going to work and have clearly taken advantage of the recent drop in share price

[clarkey26] 19/10/2016 12:47

I am confused! Am I missing something I thought they already held 25%. This seems to be supported by what is on Summit website re major shareholder holdings as at end of Sept

[freedosh] 19/10/2016 12:45

Lansdowne use wise and informed medical scientific advice
Enough said

[someuwin] 19/10/2016 12:43

Yes, Lansdowne Partners holding over 25% of SUMM is a tremendous vote of confidence.

[someuwin] 19/10/2016 10:50

Quiet day here - so far.

[patviera] 18/10/2016 18:00

Freedosh You are a perma bull!!However I must say under 2 pounds these are a steal And I will continue to add to my holdings in dipsEven though GE is still here!!

[waterloo01] 18/10/2016 15:17

Credit Suisse projects roughly $400 million in annual sales for EXONDYS 51 by 2020, but the firm also sees value elsewhere.

“We estimate unadjusted peak sales for Exon 53 and 45 indications of ~$670 million and ~$700 million respectively and assume a 15 percent probability of success to each exon target,” Young explained.


I make that $2.6bn if one could reach 100% of the population. Even if it sells for 50% of SRPT drug that's over $1.3bn sales and in a similar timeframe. (If goes to timeline, looking for approvals in 2019 and peak sales 2021?)

[waterloo01] 18/10/2016 11:48

See Griffiths is selling down on a number of stocks.

[freedosh] 17/10/2016 22:25

Big trades look like rolled T trades. Second (the buys) marked as C. I.e. Conditions
Current share price reflects this sort of trading activity and bears no relationship to future value IMO
See JPM for a (rather modest) better future estimate

[luminoso] 17/10/2016 20:43

Ahead of the game, I hope !

[waterloo01] 17/10/2016 20:01

JMP are rather out of step....

Summit Therapeutics price target raised to $42 from $24 at JMP Securities

[luminoso] 17/10/2016 18:04

Looking at share price action, down sharply, I suspect they were sales possibly reported late. As AIM is all smoke and mirrors, they could have been buys too. I still wonder if it is Griffiths offloading in an orderly manner as poss.

[freemoney1] 17/10/2016 17:36

My only question is could it be a new II building a position or just brokers moving shares between themselves. I guess we'll find out if the pattern continues. GLA

[chrisatrdg] 17/10/2016 17:26

I agree with waterloo01 the shares marked black are at the mid-point & when I have bought shares at mid-point they have been shown in black.QED

[waterloo01] 17/10/2016 16:30

Are you sure they were sales? If trade time correct (often not) then they are buys.

I think we might hear about next steps re RDZ this month, but I've been wrong before.

[luminoso] 17/10/2016 15:45

Another big dump of shares reported on AIM this afternoon. Explains the fall.